Erlotinib intermediates manufacturer
Nintedanib is the first FDA-approved drug for the management of idiopathic pulmonary fibrosis (IPF), a rare but often fatal lung disease. Nintedanib is believed to exert its mechanism of action by inhibiting multiple receptor tyrosine kinases, including those that have been implicated in the pathogenesis of IPF (i.e., fibroblast growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor). Nintedanib also inhibits nonreceptor tyrosine kinases, although the contribution of this inhibition in the efficacy of the drug is unknown.
Specification
Product name: Nintedanib
Cas No.: 656247-17-5
Einecs No.: 1592732-453-0
MF: C31H33N5O4
Purity: 99%
| Test | Specification | Result |
| Nintedanib Appearance | Off-white powder | Conforms |
| Moisture | ≤1.5% | 0.15% |
| Assay(By HPLC) | ≥99.0% | 99.5% |
| Storage | Store in a tightly closed container in a cool and dry place, below 20℃. | |
| Conclusion | Confirm to enterprise standard | |
Function
Nintedanib function is antiinflammatory and antifibrotic agent that is used to treat idiopathic pulmonary fibrosis.
Antiinflammatory and anti fibrotic agent that is used to treat idiopathic pulmonary fibrosis.
Application
Nintedanib typical application area: Applied in pharmaceutical field.
Packaging Details
25kgs packaging Fiber drum outside and plastic bag inside 1-25kgs packaging aluminium bag outside and double plastic bag inside
Delivery Detail: within 3 days when get the payment
Shipping:
We have Professional shipping agent, based on customers ' demand for transport
By express :FEDEX,DHL,EMS ,UPS,TNT ect.
By SEA and By AIR
